Fight over $1,100 hepatitis C pills awaits next move by CVS

Gilead Sciences may perhaps, in the finish, be forced to supply a lower price tag for its $94,500 hepatitis C drug. The biotechnology firm could have no choice but to negotiate its personal discounts with CVS Wellness and other drug advantage managers, say... 

The biotechnology firm could have no choice but to negotiate its personal discounts with CVS Wellness and other drug advantage managers, say analysts, after rival drugmaker AbbVie announced the deal Monday to block Gilead's pill Harvoni from a list of medicines covered by Express Scripts Holding Co.

Express Scripts manages pharmacy positive aspects for about 85 million individuals in the U.S., although CVS had about 26 % of the pharmacy advantages marketplace in the U.S. final year, behind Express Scripts, according to the U.S. Division of Labor.

"Does Gilead truly want to be blocked from half of the U.S. population?" John Kreger, an analyst at William Blair & Co., said in a phone interview Monday. "They would be the most motivated to reduce a deal with CVS."

Read more...

Labels: , , , ,